The UCLA multidisciplinary pediatric oncology team will continue to participate in the cooperative clinical research programs of the Childrens Cancer Study Group (CCSG). We propose to admit eligible patients to the appropriate treatment, epidemiology and special studies of the Group. Our patient accrual has doubled in the 1st 2-3 years and, with the recent addition of an affiliate institution, we anticipate a further increase in our enrollment of patients onto therapeutic studies. We shall provide accurate and timely clinical data to the operations office, appropriate clinical research specimens to Group investigators, and prompt responses to requests for general information, critiques of manuscripts, and reviews of proposed studies. The UCLA faculty will provide scientific leadership to CCSG by serving as members and chairpersons of various study committees, strategy groups, task forces, and discipline committees. UCLA investigators have participated actively in the planning and leadership of treatment studies, biologic assessment studies, discipline committees, and strategy groups of CCSG. We shall continue to participate in and accept specific quality control responsibility for marrow transplantation studies of ALL, ANLL, and neuroblastoma. We shall continue to provide leadership for discipline committees in the areas of nursing, psychology and tumor immunology. Our record of leadership is evidenced by the publication of 23 abstracts, 20 peer-review papers, and 15 invited articles or reviews regarding our CCSG activities during the last five year grant period. Newly recruited faculty will provide leadership in molecular oncology and innovative approaches to the treatment of brain tumors. UCLA will continue to perform local and regional innovative pilot studies with the goal that promising therapeutic approaches will be adopted for Group-wide trail. Finally, UCLA shall continue to provide special clinical resources (e.g., in allogeneic and autologous bone marrow transplantation) and laboratory resources (e./g., immunologic analyses of pediatric malignancies and purging marrow of tumor cells to allow autologous marrow transplantation) for the accomplishment of Group-wide scientific goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA027678-11
Application #
3556887
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1980-12-01
Project End
1993-11-30
Budget Start
1990-02-10
Budget End
1990-11-30
Support Year
11
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Neudorf, Steven; Sanders, Jean; Kobrinsky, Nathan et al. (2004) Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 103:3655-61
Seitzman, Robin L; Glover, Dorie A; Meadows, Anna T et al. (2004) Self-concept in adult survivors of childhood acute lymphoblastic leukemia: a cooperative Children's Cancer Group and National Institutes of Health study. Pediatr Blood Cancer 42:230-40
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Cairo, M S; Krailo, M D; Morse, M et al. (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 16:594-600
Wells, R J; Arthur, D C; Srivastava, A et al. (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16:601-7
Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33
Cooper, R; Khakoo, Y; Matthay, K K et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol 36:623-9
Meyers, P A; Krailo, M D; Ladanyi, M et al. (2001) High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 19:2812-20

Showing the most recent 10 out of 21 publications